Rituximab Market Outlook:
Rituximab Market size was over USD 5.11 billion in 2025 and is poised to exceed USD 22.16 billion by 2035, growing at over 15.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of rituximab is evaluated at USD 5.84 billion.
The increasing incidences of non-Hodgkin’s lymphoma (NHL) are expected to boost the market growth of rituximab. As per the American Cancer Society, NHL is one of the most common diseases in the USA. Around 77,200 cases were registered in 2020 in the US, the incidences are anticipated to grow rapidly due to the rising cases of cancer in the region.
In case of an autoimmune disease, the immune system attacks the healthy cells of the body. Thus, the rising prevalence of autoimmune diseases is likely to accelerate the growth of the rituximab market. According to the reports by University of Oxford, about 22 million are affected by autoimmune diseases yearly. These factors are bolstering the market growth of rituximab.
